Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Ophthalmology

The Biology and Biology-Based Testing of Panuveitis

At a Glance

Idiopathic panuveitis is an autoimmune condition where your immune system attacks your eye without a known cause. Doctors must run extensive tests to rule out serious underlying infections before starting immunosuppressants, as treating a hidden infection with steroids can cause permanent blindness.

When you are diagnosed with idiopathic panuveitis, your immune system is essentially attacking your eye without a clear external trigger [1]. Understanding the biology of this attack explains why your doctor performed so many tests before starting treatment.

The Biology of the Attack

In a healthy eye, the immune system remains quiet. In panuveitis, this “immune privilege” is broken [2]. Specialized white blood cells enter the eye and release chemical messengers called cytokines [3][4]. These act like an alarm system, calling in more inflammatory cells:

  • TNF-alpha: A powerful “master” cytokine that drives much of the swelling and tissue destruction [2][5].
  • Interleukin-6 (IL-6): This messenger increases the permeability of blood vessels, contributing to “leaky” vessels that cause retinal swelling [2][6].
  • Interleukin-17 (IL-17): A cytokine that can lead to the death of retinal cells [3][7].

These specific cytokines (TNF-alpha, IL-6, IL-17) are the exact targets that newer biologic drugs are designed to block in order to stop the inflammation [8][9].

Ruling Out the “Mimics”

Because the inflammation in idiopathic panuveitis looks similar to several other serious diseases, your doctor had to play “medical detective.”

Condition How it Differs from Idiopathic Panuveitis How It’s Ruled Out
Sarcoidosis Causes “granulomas” (clumps of immune cells) and often affects the lungs [10]. Chest X-ray/CT scan and blood tests for ACE or lysozyme [11].
Behçet’s Disease Often involves painful mouth or genital sores and severe retinal vasculitis [12][13]. Physical exam and checking for a “shifting hypopyon” (fluid in the front of the eye) [13].
Vogt-Koyanagi-Harada (VKH) Typically involves fluid under the retina (exudative detachment) and neurological symptoms like headaches or hearing loss [14][15]. Detailed eye imaging (OCT) and asking about headaches or skin changes [16].

The Critical Importance of Ruling Out Infection

The most dangerous mistake in treating panuveitis is mistaking an infection for an autoimmune “idiopathic” condition [17].

Standard treatments for idiopathic panuveitis involve corticosteroids or immunosuppressants, which “turn off” the immune system [18][19]. If an active infection—such as tuberculosis (TB) or syphilis—is present, turning off the immune system is like removing the guards from a prison [17][20].

  • The Risk: Without the immune system to hold them back, the bacteria or viruses can multiply rapidly, leading to permanent blindness or systemic illness [21][22].
  • The Solution: If an infection is found, the treatment changes entirely. Instead of suppressing the immune system, you receive targeted antibiotics or antivirals [20][23].

Only after these infectious and systemic mimics have been cleared can your doctor safely conclude your condition is “idiopathic” [1][24].

Common questions in this guide

Why does my doctor need to do so many tests for panuveitis?
Because panuveitis looks similar to many other diseases, your doctor must play medical detective. They run blood tests and imaging to ensure the inflammation isn't being caused by a hidden infection or another specific autoimmune condition before starting treatment.
What is the risk to my eyes if I start steroids before ruling out an infection?
Taking steroids suppresses your immune system. If you have an active underlying infection like tuberculosis or syphilis, suppressing your immune system allows the bacteria or viruses to multiply rapidly, which can lead to permanent blindness or serious illness.
What are cytokines and how do they affect my eyes?
Cytokines are chemical messengers that act like an alarm system, calling inflammatory white blood cells into your eye. In panuveitis, certain cytokines cause blood vessels to leak and tissue to swell, which can severely damage the retina.
How do doctors tell the difference between idiopathic panuveitis and Vogt-Koyanagi-Harada (VKH) disease?
Doctors use detailed eye imaging to look for specific signs, such as fluid under the retina. They will also ask if you are experiencing neurological symptoms like persistent headaches, hearing loss, or skin color changes, which are common in VKH but not typical in idiopathic panuveitis.
What does an idiopathic panuveitis diagnosis mean?
The term 'idiopathic' means the condition has no clear external cause or trigger. Your doctor will only give you this specific diagnosis after completely ruling out underlying infections and other autoimmune diseases like sarcoidosis or Behçet’s disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Since we've ruled out sarcoidosis and Behçet's, were there any borderline test results that we should keep an eye on?
  2. 2.What is the risk to my eyes if we start steroids before we are entirely sure an infection like tuberculosis or syphilis isn't present?
  3. 3.Are there any specific imaging findings, like fluid under the retina, that help distinguish my case from VKH?
  4. 4.If my symptoms change to include mouth sores or skin rashes, how would that change our idiopathic diagnosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Distinguishing Uveitis Secondary to Sarcoidosis From Idiopathic Disease: Cardiac Implications.

    Han YS, Rivera-Grana E, Salek S, Rosenbaum JT

    JAMA ophthalmology 2018; (136(2)):109-115 doi:10.1001/jamaophthalmol.2017.5466.

    PMID: 29327057
  2. 2

    Factors Influencing Aqueous Proinflammatory Cytokines and Growth Factors in Uveitic Glaucoma.

    Ohira S, Inoue T, Iwao K, et al.

    PloS one 2016; (11(1)):e0147080 doi:10.1371/journal.pone.0147080.

    PMID: 26771310
  3. 3

    Roles of interleukin-17 in uveitis.

    Guedes MC, Borrego LM, Proença RD

    Indian journal of ophthalmology 2016; (64(9)):628-634 doi:10.4103/0301-4738.194339.

    PMID: 27853008
  4. 4

    Interleukin-17A in diabetic retinopathy: The crosstalk of inflammation and angiogenesis.

    Li J, Zhao T, Sun Y

    Biochemical pharmacology 2024; (225()):116311 doi:10.1016/j.bcp.2024.116311.

    PMID: 38788958
  5. 5

    Adalimumab in the treatment of non-infectious uveitis.

    Burek-Michalska A, Turno-Kręcicka A

    Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2020; (29(10)):1231-1236 doi:10.17219/acem/125431.

    PMID: 33125196
  6. 6

    Genetic Predisposition and Inflammatory Inhibitors in COVID-19: Where Do We Stand?

    Sagris M, Theofilis P, Antonopoulos AS, et al.

    Biomedicines 2022; (10(2)) doi:10.3390/biomedicines10020242.

    PMID: 35203452
  7. 7

    Protective role of IL-17-producing γδ T cells in a laser-induced choroidal neovascularization mouse model.

    Chang YH, Hsing CH, Chiu CJ, et al.

    Journal of neuroinflammation 2023; (20(1)):279 doi:10.1186/s12974-023-02952-1.

    PMID: 38007487
  8. 8

    Efficacy of golimumab in patients with refractory non-infectious panuveitis.

    Tungsattayathitthan U, Tesavibul N, Choopong P, et al.

    Scientific reports 2024; (14(1)):2179 doi:10.1038/s41598-024-52526-1.

    PMID: 38273077
  9. 9

    Comparison of conventional immunosuppressive drugs versus anti-TNF-α agents in non-infectious non-anterior uveitis.

    Leclercq M, Langlois V, Girszyn N, et al.

    Journal of autoimmunity 2020; (113()):102481 doi:10.1016/j.jaut.2020.102481.

    PMID: 32586650
  10. 10

    Demographic Features, Diagnoses and Real-World Clinical Management of Uveitis in Japan.

    Hayashi I, Keino H, Nakayama M, et al.

    Ocular immunology and inflammation 2025; (33(7)):1077-1085 doi:10.1080/09273948.2024.2449179.

    PMID: 39792467
  11. 11

    Patterns of uveitis in children at the apex institute for eye care in India: analysis and review of literature.

    Takkar B, Venkatesh P, Gaur N, et al.

    International ophthalmology 2018; (38(5)):2061-2068 doi:10.1007/s10792-017-0700-6.

    PMID: 28861733
  12. 12

    The Pattern of Uveitis among Chinese, Malays, and Indians in Singapore.

    Siak J, Jansen A, Waduthantri S, et al.

    Ocular immunology and inflammation 2017; (25(sup1)):S81-S93 doi:10.1080/09273948.2016.1188968.

    PMID: 27419535
  13. 13

    Clinical Characteristics and Treatment of 308 Panuveitis Patients over 10 Years: Results from the KKESH Uveitis Survey Study Group.

    Arevalo JF, Lasave AF, Gupta V, et al.

    Ocular immunology and inflammation 2019; (27(8)):1296-1304 doi:10.1080/09273948.2018.1523436.

    PMID: 30303435
  14. 14

    A Case of Vogt-Koyanagi-Harada Disease: Diagnosis Based on the Presence of Vitiligo and Sunset Glow Fundus Without Ocular Symptoms.

    Tsutsui H, Fukuda K, Nakajima I, Yamashiro K

    Cureus 2025; (17(1)):e78209 doi:10.7759/cureus.78209.

    PMID: 40026970
  15. 15

    Clinical characteristics and visual outcome of Vogt Koyanagi Harada disease patients in a specialized eye hospital in Nepal.

    Bastola Paudel J, Manandhar A, Shrestha S

    Journal of Nepal Health Research Council 2025; (23(1)):165-169 doi:10.33314/jnhrc.v23i01.5601.

    PMID: 40776499
  16. 16

    [VOGT-KOYANAGI-HARADA SYNDROME].

    Cohen D, Ben-Arie-Weintrob Y, Hareuveni-Blum T, Naaman E

    Harefuah 2025; (164(3)):183-187.

    PMID: 40134159
  17. 17

    Diagnosis and treatment of tuberculosis presenting as uveitis based on stochastic simulation in systems biology.

    Liu L, Gou Y, Chen L, Zong Z

    Biotechnology & genetic engineering reviews 2024; (40(4)):4098-4107 doi:10.1080/02648725.2023.2205197.

    PMID: 37125900
  18. 18

    Non-Infectious Uveitis: Optimising the Therapeutic Response.

    Airody A, Heath G, Lightman S, Gale R

    Drugs 2016; (76(1)):27-39 doi:10.1007/s40265-015-0502-y.

    PMID: 26645222
  19. 19

    Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis.

    Favalli EG, Bugatti S, Klersy C, et al.

    Arthritis research & therapy 2020; (22(1)):290 doi:10.1186/s13075-020-02395-6.

    PMID: 33380344
  20. 20

    [Panuveitis with oral and genital ulcer misdiagnosed as Behcet's disease: two cases report and literature review].

    Wang Y, Yang L, Zhang ZL

    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2016; (48(5)):910-914.

    PMID: 27752180
  21. 21

    [Treatment of ocular tuberculosis-an update].

    Brönnimann LC, Zimmerli S, Garweg JG

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2020; (117(11)):1080-1086 doi:10.1007/s00347-020-01099-1.

    PMID: 32296921
  22. 22

    Types of Fundus Involvement in Intraocular Tuberculosis.

    Kaya M, Ömeroglu Şimşek G, Ucan ES, et al.

    Turkish thoracic journal 2022; (23(5)):322-330 doi:10.5152/TurkThoracJ.2022.21207.

    PMID: 35943072
  23. 23

    Tuberculous Posterior Sclero-Uveitis with Features of Vogt-Koyanagi-Harada Uveitis: An Unusual Case.

    Kalogeropoulos D, Kitsos G, Konstantinidis A, et al.

    The American journal of case reports 2017; (18()):367-374 doi:10.12659/ajcr.903304.

    PMID: 28389634
  24. 24

    Pattern of uveitis in a referral ophthalmology center in Northeastern Thailand.

    Wannapanich T, Chuenchaem W, Luanratanakorn P, Laovirojjanakul W

    Journal of ophthalmic inflammation and infection 2024; (14(1)):23 doi:10.1186/s12348-024-00400-6.

    PMID: 38819497

This page explains the biological mechanisms and diagnostic testing for idiopathic panuveitis for educational purposes only. Always consult your ophthalmologist or rheumatologist to discuss your specific test results and treatment plan.

Get notified when new evidence is published on Idiopathic panuveitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.